Targeting PI3K Inhibitor Resistance in Breast Cancer with Metabolic Drugs

Using in vitro and orthotopic xenograft mouse models, scientists demonstrated that constitutively active mTORC1 signaling rendered PI3K inhibitor-resistant breast cancer exquisitely sensitive to various drugs targeting cancer metabolism.